Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37075781

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2023 Jun 3
First author
Kelley RK

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 Jun 3;401(10391):1826-1827. doi: 10.1016/S0140-6736(23)00767-5.
    note
    Source null
    related pmid
    37075782
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2023 Jul;20(7):425. doi: 10.1038/s41571-023-00772-z.
    note
    Source null
    related pmid
    37106149
    relationship
    Comment in
  3. citation
    Lancet. 2023 Sep 16;402(10406):964. doi: 10.1016/S0140-6736(23)01904-9.
    note
    Source null
    related pmid
    37716770
    relationship
    Erratum in
  4. citation
    Transl Cancer Res. 2024 Jan 31;13(1):22-24. doi: 10.21037/tcr-23-1763.
    note
    Source null
    related pmid
    38410206
    relationship
    Comment in
  5. citation
    Lancet. 2024 Mar 23;403(10432):1140. doi: 10.1016/S0140-6736(24)00545-2.
    note
    Source null
    related pmid
    38521561
    relationship
    Erratum in

Authors and identifiers

  1. name
    Kelley RK
    type
    Author
  2. name
    Ueno M
    type
    Author
  3. name
    Yoo C
    type
    Author
  4. name
    Finn RS
    type
    Author
  5. name
    Furuse J
    type
    Author
  6. name
    Ren Z
    type
    Author
  7. name
    Yau T
    type
    Author
  8. name
    Klümpen HJ
    type
    Author
  9. name
    Chan SL
    type
    Author
  10. name
    Ozaka M
    type
    Author
  11. name
    Verslype C
    type
    Author
  12. name
    Bouattour M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kelley RK
    type
    Author
  2. name
    Ueno M
    type
    Author
  3. name
    Yoo C
    type
    Author
  4. name
    Finn RS
    type
    Author
  5. name
    Furuse J
    type
    Author
  6. name
    Ren Z
    type
    Author
  7. name
    Yau T
    type
    Author
  8. name
    Klümpen HJ
    type
    Author
  9. name
    Chan SL
    type
    Author
  10. name
    Ozaka M
    type
    Author
  11. name
    Verslype C
    type
    Author
  12. name
    Bouattour M
    type
    Author
bibliography ids
  1. nci-bib-f18d3f9434a119381603d31a
book metadata
content sha256
d325eda4bccb96e83bb47bde2839a3c7f40d5a9a5b41dd4066a42878e968100b
document type
citation
dois
  1. 10.1016/S0140-6736(23)00727-4
electronic publication date
display
2023 Apr 16
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37075781
immutable id
pubmed:37075781@d325eda4bccb96e83bb47bde2839a3c7f40d5a9a5b41dd4066a42878e968100b
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10391
name
Lancet (London, England)
nlm unique id
2985213R
pages
1853-1865
volume
401
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 Jun 3;401(10391):1826-1827. doi: 10.1016/S0140-6736(23)00767-5.
    note
    Source null
    related pmid
    37075782
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2023 Jul;20(7):425. doi: 10.1038/s41571-023-00772-z.
    note
    Source null
    related pmid
    37106149
    relationship
    Comment in
  3. citation
    Lancet. 2023 Sep 16;402(10406):964. doi: 10.1016/S0140-6736(23)01904-9.
    note
    Source null
    related pmid
    37716770
    relationship
    Erratum in
  4. citation
    Transl Cancer Res. 2024 Jan 31;13(1):22-24. doi: 10.21037/tcr-23-1763.
    note
    Source null
    related pmid
    38410206
    relationship
    Comment in
  5. citation
    Lancet. 2024 Mar 23;403(10432):1140. doi: 10.1016/S0140-6736(24)00545-2.
    note
    Source null
    related pmid
    38521561
    relationship
    Erratum in
outcomes validated
false
pmid
37075781
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
6e2bae8f9f080fe0de8982a029a9f9ad242bc5372288f851a46712823d218819
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Jun 3
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37075781/
title
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice